| Not Yet Recruiting | Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) NCT07441200 | NS Pharma, Inc. | Phase 2 |
| Not Yet Recruiting | Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension NCT07464184 | University Hospital, Rouen | N/A |
| Not Yet Recruiting | Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension NCT06176118 | Vanderbilt University Medical Center | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Pa NCT07481981 | Insmed Incorporated | Phase 3 |
| Not Yet Recruiting | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) NCT07365332 | Inhibikase Therapeutics | Phase 3 |
| Not Yet Recruiting | Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice NCT07374302 | Caio Júlio César dos Santos Fernandes | — |
| Not Yet Recruiting | A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia NCT07312227 | Massachusetts General Hospital | — |
| Not Yet Recruiting | Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hyp NCT07366879 | Golden Jubilee National Hospital | N/A |
| Active Not Recruiting | Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) NCT07391228 | Alessandra Gorini | — |
| Recruiting | 129 Xenon Imaging in Patients Treated With Sotatercept NCT06351345 | Bastiaan Driehuys | Phase 2 |
| Not Yet Recruiting | A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin NCT06603285 | Excelsior | — |
| Not Yet Recruiting | A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults NCT07143448 | 35Pharma Inc | Phase 1 |
| Not Yet Recruiting | A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets NCT05660863 | Guangzhou Magpie Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | Rutgers University Study of the Genetics of Pulmonary Hypertension NCT07217522 | Rutgers, The State University of New Jersey | — |
| Recruiting | The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension NCT07013149 | University of Sao Paulo General Hospital | — |
| Recruiting | PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch NCT06998329 | University of Sao Paulo General Hospital | — |
| Enrolling By Invitation | Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension NCT06992440 | Gustavo A Heresi, MD, MS | Phase 2 |
| Recruiting | Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate NCT06658522 | Amsterdam UMC, location VUmc | Phase 4 |
| Active Not Recruiting | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY NCT06925750 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce NCT06850792 | University of Sao Paulo General Hospital | N/A |
| Recruiting | Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults NCT06429930 | Pharmosa Biopharm Inc. | Phase 1 |
| Recruiting | A Trial of "APL-9796'' in Adults With Pulmonary Hypertension NCT06846554 | Apollo Therapeutics Ltd | Phase 2 |
| Completed | The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI NCT06907693 | Prisma Health-Upstate | — |
| Recruiting | Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension NCT06804122 | Tampere Heart Hospital | N/A |
| Recruiting | Mobile Health Intervention to Improve Exercise in Pediatric PH NCT06549452 | Vanderbilt University Medical Center | N/A |
| Not Yet Recruiting | The CardioMEMS Vericiguat Heart Failure Trial NCT06671990 | Finn Gustafsson | Phase 4 |
| Completed | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) NCT06664801 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Mic NCT06481852 | University of Minnesota | Phase 1 |
| Recruiting | A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension NCT06554301 | China National Center for Cardiovascular Diseases | Phase 1 |
| Active Not Recruiting | Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension NCT06543745 | University of Pennsylvania | N/A |
| Active Not Recruiting | Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) NCT06274801 | GB002, Inc. | Phase 3 |
| Recruiting | 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) NCT06104228 | Bastiaan Driehuys | Phase 2 |
| Withdrawn | Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension NCT04254289 | University of Michigan | N/A |
| Recruiting | Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH NCT06350032 | AOP Orphan Pharmaceuticals AG | Phase 3 |
| Enrolling By Invitation | A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary NCT06445673 | AOP Orphan Pharmaceuticals AG | — |
| Recruiting | Myocardial Work Evaluation in Patients With PAH NCT06567379 | Central Hospital, Nancy, France | — |
| Completed | Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonar NCT06409026 | Mayo Clinic | Phase 4 |
| Recruiting | Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Bre NCT06528418 | ChromX Health | — |
| Not Yet Recruiting | IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy NCT06072937 | HeartPoint Global | N/A |
| Active Not Recruiting | Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension NCT06683040 | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Phase 2 / Phase 3 |
| Completed | Melatonin for Pulmonary Hypertension in Full Term Neonates NCT06685679 | Ain Shams University | Phase 3 |
| Recruiting | Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension NCT06454838 | Gazi University | — |
| Completed | Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets NCT06484673 | Humanis Saglık Anonim Sirketi | Phase 1 |
| Completed | Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) NCT06384534 | University of Zurich | N/A |
| Unknown | Assessing the Utility of Submaximal CPET in Treatment Management of PAH NCT05977933 | Shape Medical Systems, Inc. | — |
| Recruiting | Taiwan Interstitial Lung Disease Multi-center Investigation and Registry NCT06476470 | Taichung Veterans General Hospital | — |
| Recruiting | Repurposing Valsartan May Protect Against Pulmonary Hypertension NCT06053580 | University of Washington | Phase 2 |
| Recruiting | Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension NCT06405126 | KU Leuven | — |
| Unknown | The Effects of the Otago Exercise Program NCT06172790 | Istanbul University - Cerrahpasa | N/A |
| Recruiting | A Study of Pulmonary Hypertension Peripheral Limitations NCT05968859 | Mayo Clinic | N/A |
| Completed | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) NCT05934526 | GB002, Inc. | Phase 3 |
| Recruiting | Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patient NCT06317805 | AOP Orphan Pharmaceuticals AG | Phase 4 |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmon NCT06137742 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Pulmonary Hypertension SOLAR NCT04778046 | Bastiaan Driehuys | Phase 2 |
| Completed | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Part NCT05975905 | Keros Therapeutics, Inc. | Phase 2 |
| Unknown | Apabetalone for Pulmonary Arterial Hypertension NCT04915300 | Laval University | Phase 2 |
| Unknown | High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assesse NCT06092424 | University of Zurich | N/A |
| Recruiting | FreeFlow Percutaneous Atrial Septal Shunt for IPAH NCT06605794 | Shanghai Zhongshan Hospital | N/A |
| Completed | Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults NCT05938946 | Pharmosa Biopharm Inc. | Phase 1 |
| Completed | Supervised Endurance Training Among Pulmonary Arterial Hypertension Patients NCT05947032 | Riphah International University | N/A |
| Terminated | Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin NCT05060315 | United Therapeutics | — |
| Recruiting | Pulmonary Hypertension: Intensification and Personalisation of Combination Rx NCT05825417 | Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 |
| Unknown | Anti-CD20 Antibodies for Treatment of SLE-PAH NCT05828147 | Chinese SLE Treatment And Research Group | Phase 4 |
| Completed | A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) NCT05818137 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension NCT06550648 | Cairo University | — |
| Terminated | Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants NCT05764265 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension NCT05564637 | Mayo Clinic | Phase 2 |
| Completed | Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablet NCT06180096 | Humanis Saglık Anonim Sirketi | Phase 1 |
| Active Not Recruiting | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) NCT05649748 | Insmed Incorporated | Phase 2 / Phase 3 |
| Withdrawn | Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH NCT05618093 | University of California, Los Angeles | N/A |
| Completed | Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA NCT05624242 | Central Hospital, Nancy, France | — |
| Recruiting | Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH) NCT05745961 | Imperial College London | — |
| Unknown | Non-invasive Pulmonary Artery Prediction (ADOPTS) NCT05641675 | Silverleaf Medical Sciences INC | — |
| Recruiting | Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) NCT05587712 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Telerehabilitation Program Via Videoconference PAH - Randomized Clinical Trial NCT05655481 | University of Nove de Julho | N/A |
| Completed | Dapagliflozin in Pulmonary Arterial Hypertension NCT05179356 | Mads Ersbøll | Phase 2 |
| Recruiting | The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study NCT05464095 | Vanderbilt University Medical Center | N/A |
| Unknown | TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study NCT04570228 | SoniVie Inc. | N/A |
| Active Not Recruiting | Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertens NCT06582459 | The First People's Hospital of Neijiang | — |
| Recruiting | REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) NCT05665556 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | — |
| Completed | A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension NCT05167825 | Janssen Pharmaceutical K.K. | Phase 3 |
| Terminated | Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) NCT05557942 | Aerovate Therapeutics | Phase 3 |
| Unknown | Non-invasive Pulmonary Artery Prediction NCT05622695 | Silverleaf Medical Sciences INC | — |
| Active Not Recruiting | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Rev NCT05203510 | United Therapeutics | Phase 4 |
| Completed | Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension NCT05521113 | Mayo Clinic | — |
| Unknown | Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension NCT04972656 | Nanjing First Hospital, Nanjing Medical University | N/A |
| Active Not Recruiting | Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension NCT05339386 | University of Kansas Medical Center | — |
| Completed | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Pa NCT05147805 | Insmed Incorporated | Phase 2 |
| Unknown | Consistency of Electrical Cardiometry and Pulmonary Artery Catheter NCT05587400 | Shanghai Zhongshan Hospital | N/A |
| Active Not Recruiting | Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) NCT05679570 | International University of Health and Welfare | Phase 2 |
| Recruiting | PET Image in PAH Patients NCT05452889 | Stephen Y. Chan | EARLY_Phase 1 |
| Terminated | Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension NCT05135000 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist NCT05427162 | Actelion | Phase 1 |
| Active Not Recruiting | Efficacy of Triple-Combination Therapy in Severe PAH-CHD NCT06196801 | Guangdong Provincial People's Hospital | — |
| Completed | Exercise Training in Patients With Pulmonary Arterial Hypertension NCT05242380 | Saglik Bilimleri Universitesi | N/A |
| Recruiting | Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension NCT05566002 | Chinese Pulmonary Vascular Disease Research Group | — |
| Completed | Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH) NCT04968210 | University of Texas Southwestern Medical Center | — |
| Recruiting | COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNg NCT05413109 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Completed | Effect of CS1 in Subjects With Pulmonary Arterial Hypertension NCT05224531 | Cereno Scientific AB | Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency an NCT05208814 | Vigonvita Life Sciences | Phase 1 |
| Recruiting | National Registry and Cohort Study of Pulmonary Vascular Disease NCT05368467 | Nanjing First Hospital, Nanjing Medical University | — |
| Terminated | A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) NCT04791514 | Insmed Incorporated | Phase 2 |
| Completed | Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) NCT04811092 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 3 |
| Completed | Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension NCT07214129 | Mansoura University | N/A |
| Completed | Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficie NCT05185011 | Vigonvita Life Sciences | Phase 1 |
| Terminated | A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) NCT05036135 | Aerovate Therapeutics | Phase 2 / Phase 3 |
| Withdrawn | miRNA and Myokines in Patients With PAH NCT03905083 | University of Pittsburgh | N/A |
| Completed | A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZEN NCT04896008 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 3 |
| Completed | Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study NCT04884971 | University of Minnesota | Phase 1 |
| Enrolling By Invitation | Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs NCT04930289 | Paragonix Technologies | — |
| Terminated | A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants NCT04955990 | Actelion | Phase 4 |
| Completed | Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension NCT04908397 | Vanderbilt University Medical Center | Phase 1 |
| Recruiting | Xenon MRI Pulm Hypertension NCT04991454 | Bastiaan Driehuys | Phase 2 |
| Completed | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 NCT05039086 | Brigham and Women's Hospital | — |
| Completed | Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and P NCT06784687 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD NCT04691154 | Liquidia Technologies, Inc. | Phase 3 |
| Unknown | Functional Exercise Tests in Patients With Systemic Sclerosis NCT04650659 | University of Aarhus | — |
| Completed | A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions NCT04813926 | Bayer | — |
| Terminated | A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magn NCT04435782 | Actelion | Phase 4 |
| Completed | HRV as a Marker of Treatment Response in PAH Arterial Hypertension NCT04451850 | University of Cincinnati | — |
| Unknown | RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists NCT05600218 | Hospital Costa del Sol | — |
| Completed | Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solut NCT04903730 | Aerami Therapeutics | Phase 1 |
| Completed | A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertens NCT04732221 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Recruiting | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) NCT07218029 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Right Atrial Fibrosis in Pulmonary Hypertension NCT04663230 | University of Giessen | — |
| Completed | Physical Activity and Various Aspects of Quality of Life in Patients With Pulmonary Arterial Hypertension (Ph- NCT06312111 | Centre of Postgraduate Medical Education | N/A |
| Completed | StratosPHere (Non-interventional Study) NCT05767918 | Papworth Hospital NHS Foundation Trust | — |
| Unknown | Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH NCT05569655 | Chinese Pulmonary Vascular Disease Research Group | N/A |
| Active Not Recruiting | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) NCT04816604 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 2 |
| Completed | Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patie NCT04808830 | Izmir Bakircay University | — |
| Completed | A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE) NCT04712669 | Altavant Sciences GmbH | Phase 2 |
| Recruiting | Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System NCT04555161 | Aria CV, Inc | N/A |
| Completed | Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension NCT04787445 | Mayo Clinic | — |
| Unknown | Prognostic Value of the Right Ventricular Function by Portable Ultrasound in Patients With Pulmonary Hypertens NCT05343091 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | — |
| Completed | Medication Reconciliation in Pulmonary Hypertension NCT04744584 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) NCT04576988 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 3 |
| Unknown | Positioning Imatinib for Pulmonary Arterial Hypertension NCT04416750 | Imperial College London | Phase 2 |
| Terminated | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH NCT04084678 | United Therapeutics | Phase 3 |
| Withdrawn | TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH NCT04280523 | Vanderbilt University Medical Center | — |
| Completed | Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension NCT04483115 | Vigonvita Life Sciences | Phase 2 |
| Unknown | A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension NCT04503733 | Gmax Biopharm LLC. | Phase 1 |
| Completed | A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag NCT04567602 | Janssen-Cilag S.p.A. | — |
| Completed | Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study NCT04266197 | Respira Therapeutics, Inc. | Phase 2 |
| Completed | A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers NCT04505137 | Gmax Biopharm Australia Pty Ltd. | Phase 1 |
| Recruiting | Pulmonary Hypertension Biorepository and Registry NCT04808596 | University of Kansas Medical Center | — |
| Unknown | Anxiety Self-management Intervention for Pulmonary Hypertension NCT04450862 | University of Sheffield | N/A |
| Withdrawn | Implantable System for Remodulin Post-Approval Study NCT03833323 | Medtronic Cardiac Rhythm and Heart Failure | — |
| Unknown | Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension NCT04528056 | RenJi Hospital | Phase 1 / Phase 2 |
| Unknown | Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score NCT04677608 | iPHNET (italian Pulmonary Hypertension NETwork) | — |
| Active Not Recruiting | Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test NCT03893500 | Stanford University | N/A |
| Unknown | Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension NCT04489251 | Medical College of Wisconsin | — |
| Active Not Recruiting | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertensi NCT04273945 | Actelion | Phase 3 |
| Recruiting | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Stan NCT04278404 | Duke University | — |
| Unknown | Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmo NCT04309838 | University Medicine Greifswald | — |
| Unknown | Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Fun NCT04241497 | Laval University | N/A |
| Recruiting | Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) NCT03838445 | V-Wave Ltd | N/A |
| Completed | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension NCT03926793 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Terminated | Olaparib for PAH: a Multicenter Clinical Trial NCT03782818 | Laval University | Phase 1 / Phase 2 |
| Terminated | Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot S NCT04090866 | University of Wisconsin, Madison | — |
| Terminated | Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil NCT03884465 | Liquidia Technologies, Inc. | Phase 2 |
| Completed | Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hy NCT05124015 | Gazi University | — |
| Terminated | Oral CXA-10 in Pulmonary Arterial Hypertension NCT04125745 | Gladwin, Mark, MD | Phase 2 |
| Completed | A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon NCT05318950 | Amsterdam UMC, location VUmc | N/A |
| Enrolling By Invitation | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Exten NCT03683186 | United Therapeutics | Phase 3 |
| Completed | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Usin NCT03950739 | United Therapeutics | Phase 1 |
| Completed | Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypert NCT04076241 | Istanbul University - Cerrahpasa | N/A |
| Completed | Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study NCT03655704 | Steeve Provencher | EARLY_Phase 1 |
| Terminated | A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1) NCT03924154 | Altavant Sciences GmbH | Phase 2 |
| Completed | A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension NCT05343637 | Respira Therapeutics, Inc. | Phase 2 |
| Completed | Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arter NCT03863990 | Bayer | — |
| Completed | Safety and Efficacy of BIA 5-1058 in PAH NCT06009185 | Bial - Portela C S.A. | Phase 2 |
| Completed | DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial NCT04282434 | University of Campania Luigi Vanvitelli | — |
| Completed | Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) NCT04316143 | Bial - Portela C S.A. | Phase 2 |
| Completed | BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension NCT04086537 | Heidelberg University | — |
| Completed | Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension NCT03554291 | University of Washington | Phase 2 |
| Completed | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension NCT03738150 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Terminated | Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study NCT03795428 | PhaseBio Pharmaceuticals Inc. | Phase 2 |
| Completed | The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hyperten NCT05948644 | Vigonvita Life Sciences | Phase 1 |
| Completed | The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia NCT04207593 | Heidelberg University | Phase 2 |
| Completed | Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH NCT03888365 | United Therapeutics | — |
| Recruiting | Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology i NCT04062565 | University of Arizona | Phase 3 |
| Completed | Subcutaneous Elafin in Healthy Subjects NCT03522935 | Roham T. Zamanian | Phase 1 |
| Withdrawn | Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension NCT03789643 | Akros Pharma Inc. | Phase 2 |
| Unknown | Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exerci NCT03718780 | Centre Hospitalier Metropole Savoie | N/A |
| Completed | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypert NCT03497689 | United Therapeutics | Phase 4 |
| Completed | A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) NCT03744637 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Algorithms to Diagnose Pulmonary Arterial Hypertension NCT05417373 | RenJi Hospital | — |
| Unknown | Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension NCT03810443 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Effects of DHEA in Pulmonary Hypertension NCT03648385 | Rhode Island Hospital | Phase 2 |
| Unknown | Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study NCT03977428 | Wuhan Asia Heart Hospital | — |
| Completed | Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension NCT05437224 | RenJi Hospital | Phase 3 |
| Terminated | A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension NCT03657095 | Lung Biotechnology PBC | Phase 3 |
| Completed | Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606 NCT04041648 | Pharmosa Biopharm Inc. | Phase 1 |
| Terminated | Olaparib for PAH: a Pilot Study NCT03251872 | Laval University | EARLY_Phase 1 |
| Completed | Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension NCT03528902 | Vanderbilt University Medical Center | Phase 2 |
| Completed | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients NCT03626688 | United Therapeutics | Phase 3 |
| Withdrawn | Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled NCT03602781 | Bellerophon Pulse Technologies | Phase 3 |
| Active Not Recruiting | A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension NCT03492177 | Actelion | Phase 2 |
| Terminated | Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects NCT03556020 | PhaseBio Pharmaceuticals Inc. | Phase 2 |
| Unknown | Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial Commun NCT03554330 | China National Center for Cardiovascular Diseases | N/A |
| Active Not Recruiting | Effects of Physical Training on Vascular Function as a Therapeutic Target in Pulmonary Hypertension NCT03550729 | Hospital Clinic of Barcelona | N/A |
| Completed | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) NCT03496207 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Completed | Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide NCT07173738 | Bial - Portela C S.A. | Phase 1 |
| Unknown | Oxygen Treatment and Pulmonary Arterial Hypertension NCT03683082 | George Papanicolaou Hospital | N/A |
| Completed | 4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Dis NCT03928002 | Centre Chirurgical Marie Lannelongue | N/A |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058 NCT03708146 | Bial - Portela C S.A. | Phase 1 |
| Completed | Angiogenic Imaging in Pulmonary Arterial Hypertension NCT03166306 | Brigham and Women's Hospital | Phase 1 / Phase 2 |
| Completed | Effect of BIA 5 1058 on Cardiac Repolarization NCT03489005 | Bial - Portela C S.A. | Phase 1 |
| Completed | A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hyperte NCT03422328 | Actelion | Phase 3 |
| Completed | Spironolactone Therapy in Chronic Stable Right HF Trial NCT03344159 | Ottawa Heart Institute Research Corporation | Phase 4 |
| Completed | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil NCT04994860 | Bial - Portela C S.A. | Phase 1 |
| Completed | Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers NCT03464864 | Mannkind Corporation | Phase 1 |
| Recruiting | DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL NCT03959748 | Polish Cardiology Association | — |
| Unknown | The PAH Platform for Deep Phenotyping in Korean Subjects NCT03933579 | Gachon University Gil Medical Center | — |
| Completed | A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis NCT03889509 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Unknown | Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) NCT03819777 | Maastricht University Medical Center | — |
| Completed | Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil NCT04675944 | Bial - Portela C S.A. | Phase 1 |
| Completed | Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics NCT04994119 | Bial - Portela C S.A. | Phase 1 |
| Completed | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan NCT04991207 | Bial - Portela C S.A. | Phase 1 |
| Terminated | Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients NCT02939599 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension NCT03282266 | Nanjing First Hospital, Nanjing Medical University | N/A |
| Recruiting | China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization NCT06954727 | China-Japan Friendship Hospital | — |
| Completed | Pulmonary Hypertension and Anastrozole Trial NCT03229499 | University of Pennsylvania | Phase 2 |
| Unknown | Biomarkers in Pediatric Congenital Heart Disease and PAH NCT04130243 | University Medical Center Groningen | — |
| Completed | Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arte NCT03187678 | Actelion | Phase 3 |
| Completed | Revatio Special Investigation for Long-term Use in Pediatric Patients NCT03364244 | Viatris Pharmaceuticals Japan Inc | — |
| Completed | Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. NCT03078907 | Actelion | Phase 4 |
| Unknown | Long-term Outcomes of Pregnant Women With PAH NCT04053296 | RenJi Hospital | — |
| Unknown | Multi-marker Approach for Risk Assessment in PAH NCT03954405 | Wuhan Asia Heart Hospital | — |
| Completed | A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertensi NCT02932410 | Actelion | Phase 3 |
| Completed | A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH NCT03315507 | PhaseBio Pharmaceuticals Inc. | Phase 1 |
| Withdrawn | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan NCT02999906 | United Therapeutics | Phase 3 |
| Active Not Recruiting | Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) NCT03288025 | The Cleveland Clinic | N/A |
| Terminated | Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients NCT02927366 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Inspiratory Muscle Training in Pulmonary Hypertension NCT03102294 | Federal University of São Paulo | N/A |
| Completed | Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States NCT03197688 | Actelion | — |
| Completed | A Mobile Health Intervention in Pulmonary Arterial Hypertension NCT03069716 | Vanderbilt University Medical Center | N/A |
| Active Not Recruiting | ADAPT - A Patient Registry of the Real-world Use of Orenitram® NCT03045029 | United Therapeutics | — |
| Completed | Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension NCT02800941 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Withdrawn | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmona NCT02882126 | United Therapeutics | Phase 4 |
| Unknown | Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension NCT03401476 | John Granton | Phase 2 |
| Completed | Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension NCT03365479 | University of Giessen | N/A |
| Withdrawn | Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH NCT03016468 | United Therapeutics | Phase 2 |
| Unknown | Impact of Rehabilitation Program on PAH Patients Treated With Macitentan. NCT03045666 | Soroka University Medical Center | N/A |
| Completed | Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension NCT02911844 | University of Pennsylvania | Phase 2 |
| Completed | Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 NCT04991181 | Bial - Portela C S.A. | Phase 1 |
| Unknown | TReatment Of Pulmonary HYpertension 1-US Study NCT02835950 | SoniVie Inc. | N/A |
| Recruiting | Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA) NCT02845518 | Central Hospital, Nancy, France | N/A |
| Withdrawn | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titr NCT02893995 | United Therapeutics | Phase 4 |
| Unknown | The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension NCT03051763 | University of Giessen | — |
| Completed | Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy NCT02891850 | Bayer | Phase 4 |
| Terminated | Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) NCT02736149 | Eiger BioPharmaceuticals | Phase 2 |
| Unknown | Stress Echo 2020 - The International Stress Echo Study NCT03049995 | Fatebenefratelli Hospital | — |
| Completed | A Registry for Patients Taking Uptravi NCT03278002 | Actelion | — |
| Active Not Recruiting | Pulmonary Vascular Disease Phenomics Program PVDOMICS NCT02980887 | The Cleveland Clinic | — |
| Withdrawn | Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension NCT02782052 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Terminated | [18F]FES PET/CT in PAH NCT02899533 | University of Pennsylvania | — |
| Terminated | Crossover Study From Macitentan or Bosentan Over to Ambrisentan NCT02885012 | Medical University of South Carolina | Phase 4 |
| Completed | The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly NCT02558231 | Actelion | Phase 3 |
| Completed | PET/MRI in PAH Patients NCT03688698 | Medical University of Bialystok | — |
| Completed | Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH NCT02734953 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 2 |
| Completed | Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension NCT03105934 | Hospital Universitari Vall d'Hebron Research Institute | N/A |
| Completed | Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension NCT03057028 | Virginia Commonwealth University | Phase 1 |
| Completed | A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) NCT02664558 | Eiger BioPharmaceuticals | Phase 2 |
| Terminated | Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH NCT02725372 | Bellerophon Pulse Technologies | Phase 3 |
| Unknown | Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH NCT02652429 | Bellerophon Pulse Technologies | Phase 3 |
| Terminated | Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension NCT02525926 | Centre Hospitalier Universitaire de Nice | N/A |
| Unknown | TReatment Of Pulmonary HYpertension 1 Study NCT02516722 | SoniVie Inc. | N/A |
| Completed | The Effect of Adding Exercise Training to Optimal Therapy in PAH NCT02961023 | National Health Service, United Kingdom | N/A |
| Terminated | Beta-blockers in Pulmonary Arterial Hypertension NCT02507011 | University of Minnesota | Phase 2 |
| Unknown | Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension. NCT03476629 | University of Nove de Julho | N/A |
| Completed | A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension NCT02676947 | Papworth Hospital NHS Foundation Trust | Phase 2 |
| Completed | Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585 NCT02746237 | Karos Pharmaceuticals | Phase 1 |
| Recruiting | Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions NCT02691689 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Terminated | Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 NCT04991194 | Bial - Portela C S.A. | Phase 1 |
| Completed | Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag NCT02471183 | Actelion | Phase 3 |
| Recruiting | Pulmonary Hypertension Association Registry NCT04071327 | Pulmonary Hypertension Association, Inc. | — |
| Unknown | Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH NCT03841344 | University of Sheffield | N/A |
| Terminated | Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Pa NCT02968901 | Actelion | Phase 4 |
| Completed | Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension NCT03612115 | Dokuz Eylul University | N/A |
| Terminated | The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study NCT02253394 | Brigham and Women's Hospital | Phase 4 |
| Completed | Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension NCT02579954 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Completed | Effect of Food on BIA 5-1058 NCT04991155 | Bial - Portela C S.A. | Phase 1 |
| Completed | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension NCT02279745 | United Therapeutics | Phase 2 |
| Completed | Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension NCT04104490 | University of Florida | — |
| Withdrawn | Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide NCT02436512 | Geno LLC | Phase 3 |
| Completed | REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension NCT02310672 | Actelion | Phase 4 |
| Completed | Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical NCT02484807 | Heidelberg University | — |
| Completed | Aerobic Exercise Training in Pulmonary Arterial Hypertension NCT02371733 | Gazi University | N/A |
| Completed | Ventricular Reversed Remodeling After LTX in PAH Patients NCT02391441 | University Medical Center Groningen | — |
| Withdrawn | Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients Wi NCT02309463 | Actelion | — |
| Completed | Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm R NCT06605326 | Guangzhou Institute of Respiratory Disease | Phase 4 |
| Completed | Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH NCT02631421 | Vanderbilt University | — |
| Completed | Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension NCT05861479 | Central Hospital, Nancy, France | — |
| Completed | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension NCT02279160 | United Therapeutics | Phase 2 |
| Terminated | A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With NCT02284737 | Nanjing First Hospital, Nanjing Medical University | Phase 4 |
| Completed | Selonsertib in Adults With Pulmonary Arterial Hypertension NCT02234141 | Gilead Sciences | Phase 2 |
| Unknown | 3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension NCT02799979 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry NCT02249923 | New York Medical College | — |
| Terminated | Effects of Oral Sildenafil on Mortality in Adults With PAH NCT02060487 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 |